Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study by Josep M. Llibre, Judith A. Aberg, Sharon Walmsley, Juan Velez, Carlos Zala, Brenda Crabtree Ramírez, Bronagh Shepherd, Rimi Shah, Andrew Clark, Allan R. Tenorio, Amy Pierce, Fangfang Du, Bo Li, Marcia Wang, Shiven Chabria, Michael Warwick-Sanders

Get full text